Search research articles
Contact Us
Filters
Showing results (31-40 of 67) with videos related to
Page
of 7
Sort By:
The New England Journal of Medicine
|
September 5, 2008
The FDA and tobacco regulation
Gregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine
|
June 7, 2007
Rosiglitazone--continued uncertainty about safety
Jeffrey M Drazen, Stephen Morrissey, Gregory D Curfman
The New England Journal of Medicine
|
November 3, 2006
Retraction: Sudbø J et al. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 2001;344:1270-8 and Sudbø J et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 2004;350:1405-13
Gregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine
|
June 24, 2009
Tobacco, public health, and the FDA
Gregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine
|
October 29, 2010
Products at risk
Gregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine
|
January 4, 2013
Affirmative action in the balance
Gregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine
|
September 8, 2010
Sibutramine--another flawed diet pill
Gregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine
|
December 13, 2005
Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8
Gregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
JAMA Internal Medicine
|
November 14, 2017
The Supreme Court Ruling in Sandoz v Amgen: A Victory for Follow-on Biologics
Ameet Sarpatwari, Abbe R Gluck, Gregory D Curfman
The New England Journal of Medicine
|
October 5, 2007
Open clinical trials
Jeffrey M Drazen, Stephen Morrissey, Gregory D Curfman
Page
of 7
Search research articles
Search
Showing results (31-40 of 67) with videos related to
Sort By:
Page
of 7
The New England Journal of Medicine
|
September 5, 2008
The FDA and tobacco regulation
Gregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine
|
June 7, 2007
Rosiglitazone--continued uncertainty about safety
Jeffrey M Drazen, Stephen Morrissey, Gregory D Curfman
The New England Journal of Medicine
|
November 3, 2006
Retraction: Sudbø J et al. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 2001;344:1270-8 and Sudbø J et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 2004;350:1405-13
Gregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine
|
June 24, 2009
Tobacco, public health, and the FDA
Gregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine
|
October 29, 2010
Products at risk
Gregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine
|
January 4, 2013
Affirmative action in the balance
Gregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine
|
September 8, 2010
Sibutramine--another flawed diet pill
Gregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
The New England Journal of Medicine
|
December 13, 2005
Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8
Gregory D Curfman, Stephen Morrissey, Jeffrey M Drazen
JAMA Internal Medicine
|
November 14, 2017
The Supreme Court Ruling in Sandoz v Amgen: A Victory for Follow-on Biologics
Ameet Sarpatwari, Abbe R Gluck, Gregory D Curfman
The New England Journal of Medicine
|
October 5, 2007
Open clinical trials
Jeffrey M Drazen, Stephen Morrissey, Gregory D Curfman
Page
of 7